Integer Holdings Stock Alert: Is It Time to Sell as Prices Near All-Time Highs?

Integer Holdings Corporation, a prominent name in the medical device manufacturing industry, has captured investors’ attention with its recent financial performances and market activities. But is this company a hidden gem poised for growth, or is it teetering on the edge of a decline? In this deep dive, we unravel the complexities of Integer’s financial health, market position, and future prospects to help you make an informed decision.

Integer Holdings Corporation is a leading contract development and manufacturing organization (CDMO) specializing in medical device design and manufacturing. They provide innovative, high-quality medical device technologies, including catheters, guidewires, implantable ports, neuromodulation devices, pacemaker batteries, and more. Integer serves global OEMs and has a strong presence in cardiac rhythm, cardio and vascular health, and neuromodulation devices.

Financial Performance and Ratios

For the full year 2024, Integer reported:

• Sales: $1.717 billion, a 10% increase from 2023.
• GAAP Income from Continuing Operations: $121 million, a 36% increase.
•  Adjusted Net Income: $184 million, an 18% increase.
• GAAP Operating Income: $208 million, a 28% increase.
• Adjusted Operating Income: $285 million, a 20% increase.
• GAAP Diluted EPS: $3.40 per share, a 29% increase.
• Adjusted EPS: $5.30 per share, a 15% increase.
• Adjusted EBITDA: $361 million, a 19% increase.
• Cash Flow from Operating Activities: $205 million.
• Total Debt: $990 million.
• Net Total Debt: $954 million.
• Leverage Ratio: 2.6 times adjusted EBITDA.

Integer Holdings Stock Price Performance

As of the latest data, Integer Holdings Corporation’s stock price is $135.22, with a market cap of approximately $4.54 billion. The stock has seen a recent decline of 5.58% from its previous close of $143.21. Over the past year, the stock price has ranged from a low of $97.49 to a high of $146.36.

Competitors and Comparison

Company	Revenue (2024)	Net Income (2024)	Market Cap	Key Products
Integer Holdings Corporation	$1.717 billion	$121 million	$4.54 billion	Catheters, guidewires, implantable ports, neuromodulation devices
Boston Scientific Corp	$11.9 billion	$2.3 billion	$75.3 billion	Cardiovascular devices, neuromodulation systems, endoscopy systems
Cardiovascular Systems Inc	$236.2 million	$30 million	$1.2 billion	Peripheral and coronary intervention systems
Micron Solutions Inc	Data not available	Data not available	Data not available	Electrophysiology catheters, guidewires
United American Healthcare Corp	Data not available	Data not available	Data not available	Medical devices, healthcare services

Key Points:

• Revenue: Integer Holdings Corporation’s revenue is significantly lower compared to Boston Scientific Corp, which leads the industry with $11.9 billion in revenue.
• Net Income: Integer’s net income is also lower compared to Boston Scientific, but it has shown a strong growth rate of 36% in 2024.
• Market Cap: Integer’s market cap is much smaller compared to Boston Scientific, reflecting its position as a smaller player in the market.
• Product Focus: Integer focuses on a range of medical devices, while Boston Scientific has a broader product portfolio including cardiovascular and neuromodulation systems.

Integer Holdings Corporation has shown impressive growth in revenue and net income, but it still lags behind larger competitors like Boston Scientific Corp in terms of overall financial metrics.

Investment Insight

This company is quite unremarkable, lacking any standout qualities, and it even trails behind its competitors in the market. Its financial performance indicators are poor, placing it below investment grade on the Investment Scoreboard. A savvy investor would certainly exclude such a company from their portfolio. We recommend reducing your holdings in this stock or considering selling all your shares entirely. Currently, there are no buy recommendations.

Integer Holdings Stock Forecast**

2025–2029 Price Targets: 

Year	MIN Target	MAX Target
2025	71.41	107.21
2026	78.63	118.04
2027	86.57	129.96
2028	95.31	143.09
2029	104.94	157.55

When to buy and Investment Tips

The stock is evidently overvalued in the market, and at the time of writing, we observe that the price is inclined toward a correction. This is hardly surprising when the calculated Equity Risk Premium is negative. This presents an excellent opportunity to sell, as the price is close to its all-time high (ATH).

Dividend Policy

Integer Holdings Corporation has not announced any specific dividend policy or share buyback program in recent reports. However, the company’s strong cash flow from operations and strategic acquisitions suggest that they may consider these options in the future.

Conclusion

While Integer Holdings Corporation has demonstrated notable growth in certain financial metrics, it faces significant challenges in outperforming its larger competitors. The current market signals suggest that the stock may be overvalued and primed for a correction. Investors are advised to exercise caution, evaluate their portfolios critically, and consider whether holding onto this stock aligns with their investment goals. With the stock price near its all-time high and lacking strong buy recommendations, this could be an opportune moment to reevaluate your position.

A cup of coffee from you for this excellent analysis.

Or Donate:

Company’s Site.

More US Stocks.

*Investment analysis involves scrutinizing over 50 different criteria to assess a company's ability to generate shareholder value. This comprehensive approach includes tracking revenue, profit, equity dynamics, dividend payments, cash flow, debt and financial management, stock price trends, bankruptcy risk, F-Score, and more. These metrics are consolidated into a straightforward Investment Scoreboard, which effectively helps predict future stock price movements.
**Use the price forecast to manage the risk of your investments.